---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-021377"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:48:33.705349+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics completes note conversion and obtains stockholder approval for private placement issuance

## Summary
- Raised gross proceeds of approximately $5.7 million in private placement of convertible notes and warrants, closed June 12 and June 30, 2025.
- On July 27, 2025, notes automatically converted into 545,598 common shares at $8.3024 per share; issued 1,384,722 warrants exercisable at same price.
- Also issued pre-funded warrants for 146,763 shares and placement agent warrants for 83,083 shares to Paulson Investment Company.
- At special meeting on July 25, 2025, shareholders approved issuance by 225,534 votes for (95.2%) and 225,161 votes for related-party issuance.
- Total votes represented 41.35% of outstanding shares, with quorum achieved; both proposals passed with overwhelming majority.

## SEC filing metadata
- accession: 0001641172-25-021377
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000164117225021377/0001641172-25-021377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000164117225021377/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-021377
- JSON: https://secwatch.observer/filing/0001641172-25-021377.json
- Plain text: https://secwatch.observer/filing/0001641172-25-021377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.